SynAct Pharma AB (SYNACT.ST)
SEK 9.69
(0.36%)
SEK 9.69
(0.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 51.83 Million SEK | 222.43% |
| 2022 | 16.07 Million SEK | -8.14% |
| 2021 | 17.5 Million SEK | 205.68% |
| 2020 | 5.72 Million SEK | -44.48% |
| 2019 | 10.31 Million SEK | 177.43% |
| 2018 | 3.71 Million SEK | 60.65% |
| 2017 | 2.31 Million SEK | -33.76% |
| 2016 | 3.49 Million SEK | 6027.54% |
| 2015 | 57 Thousand SEK | -29.63% |
| 2014 | 81 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 54.06 Million SEK | -11.46% |
| 2024 Q3 | 47.96 Million SEK | -11.27% |
| 2024 Q1 | 61.06 Million SEK | 17.8% |
| 2023 FY | 51.83 Million SEK | 222.43% |
| 2023 Q4 | 51.83 Million SEK | -21.48% |
| 2023 Q2 | 56.97 Million SEK | 9.05% |
| 2023 Q1 | 52.24 Million SEK | 224.97% |
| 2023 Q3 | 66.01 Million SEK | 15.87% |
| 2022 Q3 | 16.12 Million SEK | -48.5% |
| 2022 Q4 | 16.07 Million SEK | -0.33% |
| 2022 FY | 16.07 Million SEK | -8.14% |
| 2022 Q1 | 21.39 Million SEK | 22.26% |
| 2022 Q2 | 31.31 Million SEK | 46.37% |
| 2021 Q3 | 12.62 Million SEK | 29.44% |
| 2021 Q2 | 9.75 Million SEK | -4.92% |
| 2021 Q1 | 10.25 Million SEK | 79.13% |
| 2021 FY | 17.5 Million SEK | 205.68% |
| 2021 Q4 | 17.5 Million SEK | 38.67% |
| 2020 Q1 | 7.27 Million SEK | -29.4% |
| 2020 FY | 5.72 Million SEK | -44.48% |
| 2020 Q4 | 5.72 Million SEK | -24.93% |
| 2020 Q3 | 7.62 Million SEK | 19.7% |
| 2020 Q2 | 6.37 Million SEK | -12.47% |
| 2019 Q4 | 10.31 Million SEK | -33.35% |
| 2019 Q3 | 15.46 Million SEK | 2.2% |
| 2019 Q1 | 4.77 Million SEK | 28.44% |
| 2019 FY | 10.31 Million SEK | 177.43% |
| 2019 Q2 | 15.13 Million SEK | 217.1% |
| 2018 Q2 | 4.42 Million SEK | 8.0% |
| 2018 FY | 3.71 Million SEK | 60.65% |
| 2018 Q4 | 3.71 Million SEK | -19.94% |
| 2018 Q1 | 4.09 Million SEK | 77.2% |
| 2018 Q3 | 4.64 Million SEK | 4.84% |
| 2017 Q4 | 2.31 Million SEK | 52.39% |
| 2017 Q3 | 1.51 Million SEK | -50.32% |
| 2017 FY | 2.31 Million SEK | -33.76% |
| 2017 Q1 | 1.9 Million SEK | -45.39% |
| 2017 Q2 | 3.05 Million SEK | 60.2% |
| 2016 Q2 | 2.62 Million SEK | 0.0% |
| 2016 Q3 | 903.43 Thousand SEK | -65.55% |
| 2016 Q4 | 3.49 Million SEK | 286.6% |
| 2016 FY | 3.49 Million SEK | 6027.54% |
| 2015 FY | 57 Thousand SEK | -29.63% |
| 2014 FY | 81 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 51.373% |
| Ziccum AB (publ) | 6.38 Million SEK | -711.428% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2097.287% |
| BioArctic AB (publ) | 139.5 Million SEK | 62.844% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -49.796% |
| Mendus AB (publ) | 51.22 Million SEK | -1.189% |
| Genovis AB (publ.) | 98.04 Million SEK | 47.134% |
| Intervacc AB (publ) | 21.68 Million SEK | -139.087% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -94.077% |
| Active Biotech AB (publ) | 13.4 Million SEK | -286.821% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 58.191% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -221.611% |
| Aptahem AB (publ) | 8.99 Million SEK | -476.072% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -26.861% |
| Kancera AB (publ) | 17.97 Million SEK | -188.319% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -12.243% |
| Fluicell AB (publ) | 8.91 Million SEK | -481.425% |
| Saniona AB (publ) | 86.08 Million SEK | 39.786% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -904.924% |
| Biovica International AB (publ) | 34.76 Million SEK | -49.09% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -344.241% |
| AcouSort AB (publ) | 10.37 Million SEK | -399.46% |
| Xintela AB (publ) | 14.01 Million SEK | -269.847% |
| Abliva AB (publ) | 16.78 Million SEK | -208.885% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 75.846% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -348.042% |
| OncoZenge AB (publ) | 1.69 Million SEK | -2950.853% |
| Amniotics AB (publ) | 10.54 Million SEK | -391.457% |
| 2cureX AB (publ) | 2.93 Million SEK | -1666.065% |
| CombiGene AB (publ) | 4.15 Million SEK | -1147.209% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1071.125% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 96.689% |
| Camurus AB (publ) | 414.81 Million SEK | 87.504% |
| Corline Biomedical AB | 6.78 Million SEK | -663.5% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 15.521% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -170.476% |
| I-Tech AB | 16.2 Million SEK | -219.864% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 95.629% |
| Cyxone AB (publ) | 4.69 Million SEK | -1004.261% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -288.911% |
| Biosergen AB | 5.08 Million SEK | -919.351% |
| Cantargia AB (publ) | 54.97 Million SEK | 5.705% |
| NextCell Pharma AB | 13.68 Million SEK | -278.653% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 27.858% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -276.384% |
| Nanologica AB (publ) | 79.32 Million SEK | 34.658% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -552.082% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -897.778% |
| LIDDS AB (publ) | 3.75 Million SEK | -1280.032% |
| Lipum AB (publ) | 7.53 Million SEK | -587.636% |
| BioInvent International AB (publ) | 90.45 Million SEK | 42.695% |
| Alzinova AB (publ) | 9.33 Million SEK | -455.503% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 71.457% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -2789.298% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -180.275% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1250.547% |
| Simris Alg AB (publ) | 148.93 Million SEK | 65.198% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 27.115% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 89.25% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -306.733% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -613.967% |